Exelixis Inc
N/A
USD
N/A
N/A
...
Chart
Financials
Description
EXEL Company Description
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
EXEL Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view EXEL Smart Score
Score Breakdown
EXEL Company Description
Show More
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of EXEL by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by EXEL's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on EXEL's company Twitter account
WallStreetBets
Number of mentions of EXEL in WallStreetBets Daily Discussion
EXEL News
Recent insights relating to EXEL
CNBC Recommendations
Recent picks made for EXEL stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in EXEL
Corporate Flights
Flights by private jets registered to EXEL
Our Analysis